Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AssuraMed
Cardinal Health Builds On Generic Device Strategy With Cordis Deal
The $1.99 billion Cordis acquisition is a major step in Cardinal's strategy to build its offerings of devices with a high physician preference but for which there is limited clinical differentiation and inefficient supply chains.
Cardinal Health Strives To Be A National Player In China Not Bound By Government Policy Goals
U.S. distributor Cardinal Health is doubling down in China and expanding its current network to become a national player.
Device/Diagnostics Quarterly Deal Statistics, Q1 2013
Device companies kicked off 2013 by raising $1.1 billion via 45 transactions; the only device M&A transaction in Q1 to exceed the billion-dollar mark was Cardinal Health Inc.’s $2.07 billion acquisition of AssuraMed. Diagnostics firms began 2013 by raising a total of $286 million in the opening quarter, a 46% improvement over Q4 2012’s tally.
Deals In Depth: February 2013
Biogen paid over $3 billion to buy out Elan’s share of Tysabri. Mylan and Cardinal Health made two billion-dollar-plus acquisitions. FOPOs represented over 50% of the $827 million in biopharma financing. The $322 million in device fundraising was dominated by late-stage venture rounds.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.